Supporting Information

Nakajima et al. 10.1073/pnas.0905702106



Fig. S1. qRT-PCR for the *Bcl2l12* transcript in various tissues from WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ mice. Primers A detect the 18th to 63rd nucleotides from the AUG of the WT *Bcl2l12* mRNA. ND, not detectable.



Fig. S2. Expression of transduced proteins. Western blot analysis was performed for HA-IRF3 and Bcl2L12-YFP using anti-HA and anti-GFP antibodies.



Fig. S3. qRT-PCR for *Ifna4* mRNA. WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ MEFs transduced with HA-IRF3 and/or Bcl2L12-YFP were stimulated with poly(rI:rC) or B-DNA for the indicated periods as in Fig. 2, and *Ifna4* mRNA expression levels were measured by qRT-PCR.



Fig. S4. Hoechst staining. MEFs from WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ mice were treated as in Fig. 3*A* (*Left*) and stained with Hoechst 33342 at 18 h.



Fig. S5. Cell cycle arrest upon X-ray irradiation. Primary MEFs from WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ mice were X-ray irradiated at 5 Gy, and then DNA content was measured 24 h after irradiation.



Fig. S6. Sensitivity to apoptotic stimuli in WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ thymocytes. Cells from WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ mice were treated with ADR (1 μg/mL), X-ray (5 Gy), Fas (100 ng/mL Jo2 plus 100 ng/mL protein A) or Dex (1 μM), and then subjected to DNA content analysis at 11 h. Data were reproduced in another independent experiment.



Fig. S7. Bcl2L12-independent apoptosis by Fas. Primary MEFs from WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ mice were transduced with empty retrovirus, pBabeHA-IRF3 and/or pMSCV-Bcl2L12-YFP, treated with an agonistic Fas antibody for 18 h as in Fig. 3*A*, and stained with annexin V.



Fig. S8. The effect of caspase inhibitors on UV-induced apoptosis in MEFs. Primary MEFs from WT and *Irf3*$^{-/-}$*Bcl2l12*$^{-/-}$ mice were UV irradiated in the absence or the presence of 50 μM z-VAD-FMK (pan-caspase inhibitor) or 50 μM z-VDVAD-FMK (caspase-2 inhibitor), and then stained with annexin V at 18 h.